Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals has named Pedro Santabarbara as the new chief medical officer and Elizabeth Trehu as the new vice president of Product Development and Medical Affairs.
Subscribe to our email newsletter
Santabarbara joins Infinity following five years with PharmaMar, where he most recently led the development and approval of Yondelis (trabectedin).
Prior to PharmaMar, he served as vice president of Clinical Research Oncology at OSI Pharmaceuticals, where he led the successful approval of Tarceva (erlotinib).
Trehu joins Infinity following four years at Genzyme Corporation, where she began as vice president of Oncology Global Medical Affairs and most recently held the position of vice president and general manager, Hematology with global responsibility for Clolar (clofarabine), Campath and Fludara (fludarabine).
Infinity R&D president Julian Adams said that Pedro and Beth have distinguished track records in drug development, and they are excited to have them join our team.
"Pedro brings a wealth of experience developing and implementing clinical trial strategies that have led to the approval of five new oncology drugs," Adams said.
"In addition, Beth’s expertise medical affairs and providing strategic support for product and portfolio decisions will be instrumental as we advance our pipeline through clinical development toward commercialisation."